Company Name
Adicet Bio Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US0070021086
CIK:
0001720580
CUSIP:
004446100
Currency:
USD
Full Time Employees:
102
Phone:
650 503 9095
Website:
https://www.adicetbio.com
Fiscal Year End:
December
IPO Date:
Jan 26, 2018
Description:
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Address:
131 Dartmouth Street, Boston, MA, United States, 02116